Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia

Blood

Volumn 112, Issue 13, 2008, Pages 5111-5121

  Adamia, Sophia ^a   Reichert, Amanda A ^a   Kuppusamy, Hemalatha ^a   Kriangkum, Jitra ^a   Ghosh, Anirban ^a   Hodges, Jennifer J ^a   Pilarski, Patrick M ^a   Treon, Steven P ^b   Mant, Michael J ^a   Reiman, Tony ^a   Belch, Andrew R ^a   Pilarski, Linda M ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLUCURONOSYLTRANSFERASE; HYALURONAN SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXON; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYALURONAN SYNTHASE 1 GENE; IN VITRO SELECTION; INHERITANCE; INTRON; MULTIPLE MYELOMA; MUTATION; PLASMA CELL; PRIORITY JOURNAL; SOMATIC CELL; SPLICING DEFECT; T LYMPHOCYTE; WALDENSTROEM MACROGLOBULINEMIA; CYTOLOGY; GENETICS; HEMATOPOIETIC SYSTEM; NUCLEOTIDE SEQUENCE; PATHOLOGY; RNA SPLICING;

BASE SEQUENCE; DISEASE PROGRESSION; EXONS; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; HEMATOPOIETIC SYSTEM; HUMANS; INTRONS; MULTIPLE MYELOMA; RNA SPLICING; WALDENSTROM MACROGLOBULINEMIA;

EID: 58149374579     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-141770     Document Type: Article

References (63)

1. Buratti E, Baralle M, Baralle FE. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res. 2006;34:3494-3510.
2. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer. 2005;42:342-357.
3. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 2004;64:7647-7654.
4. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620-1628.
5. Lamolle G, Marin M, Alvarez-Valin F. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. Mutat Res. 2006;600:102-112.
6. Staalesen V, Falck J, GeislerS, etal. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene. 2004;23:8535-8544.
7. Moon SD, Park JH, Kim EM, et al. A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroid-ism-jaw tumor syndrome. J Clin Endocrinol Metab. 2005;90:878-883.
8. Pagenstecher C, Wehner M, Friedl W, et al. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet. 2006;119:9-22.
9. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63:7056-7061.
10. Adamia S, ReimanT, Crainie M, et al. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood. 2005;105:4836-4844.
11. Adamia S, Crainie M, Kriangkum J, et al. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:165-168.
12. Adamia S, Treon SP, ReimanT, et al. Single nucleotide polymorphism of hyaluronan synthase 1 gene and aberrant splicing in Waldenstroms macroglobulinemia. Clinical Lymphoma. 2005;5:253-256.
13. Simpson MA, Reiland J, Burger SR, et al. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J Biol Chem. 2001;276:17949-17957.
14. Liu N, Gao F, Han Z, et al. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res. 2001;61: 5207-5214.
15. Itano N, Sawai T, Atsumi F, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem. 2004;279: 18679-18687.
16. Itano N, KimataK. Altered hyaluronan biosynthesis in cancer progression. Semin Cancer Biol. 2008;18:268-274.
17. Yamada Y, Itano N, Narimatsu H, et al. Elevated transcript level of hyaluronan synthase1 gene correlates with poor prognosis of human colon cancer. Clin Exp Metastasis. 2004;21:57-63.
18. Yabushita H, Noguchi M, KishidaT, et al. Hyaluronan synthase expression in ovarian cancer. Oncol Rep. 2004;12:739-743.
19. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem. 2007;282:19426-19441.
20. Golshani R, Hautmann SH, Estrella V, et al. HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer. 2007;120: 1712-1720.
21. Golshani R, Lopez L, Estrella V, et al. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008;68:483-491.
22. Yabushita H, KishidaT, Fusano K, et al. Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncol Rep. 2005;13:1101-1105.
23. Carbone MA, Applegarth DA, Robinson BH. Intron retention and frameshift mutations result in severe pyruvate carboxylase deficiency in two male siblings. Hum Mutat. 2002;20:48-56.
24. Chen LL, Sabripour M, Wu EF, et al. A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene. 2005;24:4271-4280.
25. Eng L, Coutinho G, Nahas S, et al. Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene: maximum entropy estimates of splice junction strengths. Hum Mutat. 2004;23:67-76.
26. Lazzereschi D, Nardi F, TurcoA, et al. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene. 2005;24:5344-5354.
27. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet. 2001;27:55-58.
28. Serra E,Ars E, Ravella A, et al. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet. 2001;108:416-429.
29. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP. CDKN2Apoint mutations D153spl(c. 457G>T) and IVS2 + 1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. Oncogene. 2003;22:4444-4448.
30. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285-298.
31. Maquat LE. Defects in RNA splicing and the consequence of shortened translational reading frames.Am J Hum Genet. 1996;59:279-286.
32. Hentze MW, Kulozik AE. Aperfect message: RNA surveillance and nonsense-mediated decay. Cell. 1999;96:307-310.
33. Valentine CR. The association of nonsense codons with exon skipping. Mutat Res. 1998;411: 87-117.
34. Bromidge T, Lowe C, PrenticeA, Johnson S. p53 intronic point mutation, aberrant splicing and telomeric associations in a case of B-chronic lymphocytic leukaemia. Br J Haematol. 2000;111:223-229.
35. Coutinho G, Xie J, Du L, et al. Functional significance of a deep intronic mutation in the ATM gene and evidence for an alternative exon 28a. Hum Mutat. 2005;25:118-124.
36. Nichols KE, Houseknecht MD, Godmilow L, et al. Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. Hum Mutat. 2005;25:566-574.
37. Gamez-Pozo A, Palacios I, Kontic M, et al. Pathogenic validation of unique germline intronic variants of RB1 in retinoblastoma patients using mini-genes. Hum Mutat. 2007;28:1245.
38. SharpA, Pichert G, LucassenA, Eccles D. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. Hum Mutat. 2004;24:272.
39. Hansen TV, Bisgaard ML, Jonson L, et al. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet. 2008;9:58.
40. Agrawal S, Pilarski R, Eng C. Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Hum Mol Genet. 2005;14:2459-2468.
41. Hull J, Shackleton S, HarrisA.Abnormal mRNA splicing resulting from three different mutations in the CFTR gene. Hum Mol Genet. 1993;2:689-692.
42. Durie BG, Kyle RA, BelchA, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4:379-398.
43. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Walden-strom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr;30:116-120.
44. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clono-typic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood. 1998;92:2844-2855.
45. National Center for Biotechnology Information. Human Genome Resources. www.ncbi.nlm.nih.gov/projects/genome/guide/human/. Accessed July 14, 2008.
46. Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobu-linemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108:2755-2763.
47. Pros E, Larriba S, Lopez E, et al. NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing. Hum Mutat. 2006;27:1104-1114.
48. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999;94:748-753.
49. Pasqualucci L, Neri A, Baldini L, Dalla-Favera R, Migliazza A. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 2000;60:5644-5648.
50. Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood. 2007;109:3500-3504.
51. Malpeli G, Barbi S, Moore PS, et al. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. Haematologica. 2004;89:1091-1099.
52. Gaidano G, Capello D, CiliaAM, et al. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. Genes Chromosomes Cancer. 1999;24:16-23.
53. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
54. Montesinos-Rongen M, Van RD, Schaller C, WiestlerOD, DeckertM. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 2004;103:1869-1875.
55. George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood. 2001;97: 3925-3930.
56. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr Opin Oncol. 2001;13:3-7.
57. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
58. Pilarski LM, Baigorri E, Mant MJ, et al. Multiple myeloma includes CD20+ B and plasma cells that persist in patients treated with rituximab. Clin Med Oncol. 2008;2:275-285.
59. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood. 1996;87:1891-1899.
60. Pilarski LM, Adamia S, Maxwell CA, et al. Hyalu-ronan synthases and RHAMM as synergistic mediators of malignancy in B lineage cancers. In: Balazs EA, Hascall VC, eds. Hyaluronan Structure, Metabolism, Biological Activities, Therapeutic Applications. Edgewater, NJ: Matrix Biology Institute;2005:329-338
61. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell. 2003;14:2262-2276.
62. Maxwell CA, Rasmussen E, Zhan F, et al. RHAMM expression and isoform balance predicts aggressive disease and poor survival in multiple myeloma. Blood. 2004;104:1151-1158.
63. Maxwell CA, Reiman T, Ye M, Belch AR, Pilarski LM. RHAMM overexpression: a potential mechanism to generate extensive centrosomal abnormalities in multiple myeloma [abstract]. Blood. 2003;102:35a.